Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to Arrowhead, City of Hope, and More

Premium

Title: Polyconjugates for In Vivo Delivery of Polynucleotides

Patent Number: 8,658,211

Filed: Feb. 8, 2012

Lead Inventor: David Rozema, Arrowhead Research


Title: Methods and Compositions for the Specific Inhibition of Gene Expression by Double-stranded RNA

Patent Number: 8,658,356

Filed: June 3, 2011

Lead Inventor: John Rossi, City of Hope


Title: Methods for Diagnosing Colon Cancer using microRNAs

Patent Number: 8,658,362

Filed: Feb. 28, 2012

Lead Inventor: Carlo Croce, Ohio State University (Microlin Bio)


Title: microRNA-based Methods and Compositions for the Diagnosis, Prognosis, and Treatment of Breast Cancer

Patent Number: 8,658,370

Filed: Jan. 31, 2008

Lead Inventor: Carlo Croce, Ohio State University (Microlin Bio)


Title: siRNA Targeting Amyloid Beta (A4) Precursor Protein

Patent Number: 8,658,784

Filed: July 18, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)


Title: siRNA Targeting Tie-2

Patent Number: 8,658,785

Filed: Oct. 9, 2012

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.